Link Between Heart Failure, Type 2 Diabetes Medications Examined

Share this content:
Researchers found no association between heart failure and DPP-4 inhibitors vs sulfonylureas or saxagliptin vs sitagliptin.
Researchers found no association between heart failure and DPP-4 inhibitors vs sulfonylureas or saxagliptin vs sitagliptin.

(HealthDay News) — For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors vs sulfonylureas or treatment with saxagliptin vs sitagliptin, according to a study published in Diabetes Care.

Alex Z. Fu, PhD, from the Georgetown University Medical Center in Washington, D.C., and colleagues conducted an observational study using a U.S. insurance claims database. They examined the correlation between hospitalization for heart failure and treatment with DPP-4 inhibitors vs sulfonylureas (218 556 patients), and treatment with saxagliptin vs sitagliptin (112 888 patients).

The researchers found that for DPP-4 inhibitors vs sulfonylureas (reference), the hazard ratios for hospitalization for heart failure were 0.95 (95% CI, 0.78-1.15; P=.580) for patients with baseline cardiovascular disease (CVD) and 0.59 (95% CI, 0.38-0.89; P=.013) for patients without baseline CVD. 

For saxagliptin vs sitagliptin (reference), the hazard ratios for hospitalization for heart failure were 0.95 (95% CI, 0.70-1.28; P=.712) for patients with baseline CVD and 0.99 (95% CI, 0.56-1.75; P=.972) for patients without baseline CVD.

"In patients with type 2 diabetes, there was no association between hospitalization for heart failure, or other selected cardiovascular outcomes, and treatment with a DPP-4 inhibitors relative to sulfonylureas or treatment with saxagliptin relative to sitagliptin," the researchers wrote.

Several authors disclosed financial ties to Truven Health Analytics and pharmaceutical companies, including AstraZeneca, which funded the study.

Reference

  1. Fu AZ, Johnston SS, Ghannem A, et al. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. Diabetes Care. 2016;doi:10.2337/dc15-0764.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus